Ingredients | Amount Per Serving |
---|---|
Superfood Blend
|
1.3 Gram(s) |
(Ganoderma lucidum)
(Regenerative Organic Certified)
|
|
(Ashwagandha Leaf Extract, Ashwagandha Root Extract)
(Organic)
|
|
Passionfruit, Fermented
(Passiflora edulis )
(whole plant)
(Regenerative Organic Certified)
|
|
(Annona muricata )
(whole plant)
(Regenerative Organic Certified)
|
|
(Rhodiola rosea )
(root)
(Organic)
|
|
(Moringa oleifera )
(whole plant)
(Regenerative Organic Certified)
|
|
(Bacillus subtilis AB22 )
(1 Billion CFU, At time of manufacture)
|
2.15 mg |
Pullulan, Copernicia cerifera PlantPart: wax Genus: Copernicia Species: cerifera, Apple Cider Vinegar
Below is general information about the effectiveness of the known ingredients contained in the product Stress Relief. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
Below is general information about the safety of the known ingredients contained in the product Stress Relief. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
POSSIBLY SAFE ...when used orally and appropriately, short-term. Ashwagandha has been used with apparent safety in doses of up to 1250 mg daily for up to 6 months (3710,11301,19271,90649,90652,90653,97292,101816,102682,102683) (102684,102685,102687,103476,105824,109586,109588,109589,109590). ...when used topically. Ashwagandha lotion has been used with apparent safety in concentrations up to 8% for up to 2 months (111538).
PREGNANCY: LIKELY UNSAFE
when used orally.
Ashwagandha has abortifacient effects (12).
LACTATION:
Insufficient reliable information available; avoid using.
POSSIBLY SAFE ...when taken orally and appropriately. Some strains of B. subtilis are considered "generally regarded as safe" (GRAS) for use in food (110841). Bacillus subtilis has been used with apparent safety in clinical studies. B. subtilis strains BS50, B2335, CU1, MB40, MY02, or R0179 have been used with apparent safety in doses of 2-10 billion colony forming units (CFUs) daily for 2-8 weeks (107611,110841,110843,110846,110847,110848,110854,110859). One specific product, B. subtilis DE111, has been used with apparent safety in doses of one billion CFUs daily for 12 weeks or 5 billion CFUs daily for 10 weeks (110850). Another specific product (Medilac-S), containing a combination of B. subtilis R0179 and Enterococcus faecalis, has been used with apparent safety in doses providing up to 300 million CFUs of B. subtilis daily for up to 96 weeks (110853,110860).
CHILDREN:
There is insufficient reliable information available about the safety of Bacillus subtilis in children of any age.
Cases of bacteremia have occurred rarely in preterm infants given other probiotics (102416,111610,111612,111613,111850,111852,111853). The US Food and Drug Administration (FDA) has issued a warning about cases of serious infections caused by probiotics reported in very preterm or very low birth weight infants under 1000 grams (111610). Similarly, the American Academy of Pediatrics does not support the routine administration of probiotics to these infants due to conflicting data on safety and efficacy (111608).
PREGNANCY AND LACTATION:
Insufficient reliable information available when used in doses higher than those found in foods; avoid using.
POSSIBLY UNSAFE ...when used orally. Some research has found that consumption of large amounts of graviola fruit and/or tea made from graviola leaves (e.g., daily) is associated with an increased odds of having movement disorders that resemble Parkinson disease (7854).
PREGNANCY AND LACTATION: POSSIBLY UNSAFE
when used orally (7854).
LIKELY SAFE ...when used orally in food amounts. The leaves, fruit, and seeds are commonly used in foods (16341,16344,90573).
POSSIBLY SAFE ...when moringa leaf or seed is used orally and appropriately in medicinal amounts, short-term. Tablets and capsules containing up to 30 grams of moringa leaf powder have been used daily with apparent safety in clinical studies lasting up to 6 months (20578,90572,90572,97209,97210). A dried moringa seed kernel powder has also been used with apparent safety in doses of 3 grams twice daily for 3 weeks (19278). ...when moringa leaf extract is used topically and appropriately. Moringa leaf extract 2% has been used 3 times daily with apparent safety in a clinical trial lasting 3 months (112640).
POSSIBLY UNSAFE ...when moringa root or root bark are used orally. Moringa root contains spirochin, a potentially toxic alkaloid, while moringa root bark contains stimulant alkaloids similar to ephedrine. Although spirochin has not been studied in humans, animal data shows that it can cause nerve paralysis (63764).
CHILDREN: POSSIBLY SAFE
when moringa leaf is used orally and appropriately, short-term.
Powdered dried moringa leaf has been used with apparent safety in doses of 15 grams twice daily for up to 2 months (90576).
PREGNANCY: POSSIBLY SAFE
when the leaf is used orally during the second or third trimesters, short-term.
Moringa leaf powder or extract 500 mg daily for up to 4 months has been used with apparent safety during the second and third trimesters (105469,105471,105472,110645). There is insufficient reliable information available about the safety of using moringa leaf by mouth during the first trimester.
PREGNANCY: POSSIBLY UNSAFE
when the root, bark, or flower are used orally.
Traditionally, moringa root bark and gum from moringa trunk bark have been used to induce abortion. When taken orally along with black peppercorns to induce abortion, moringa root bark may cause fatality (63764). Animal research shows that moringa flower can cause uterine contractions (94634); however, this has not been assessed in humans.
There is insufficient reliable information about the safety of using moringa seed during pregnancy; avoid using.
LACTATION: POSSIBLY SAFE
when moringa leaf is used orally, short-term.
Moringa leaf powder or extract 2 grams daily has been used during lactation with apparent safety for up to 4 months (20578,90571,90573,105471,105472). There is insufficient reliable information available about the safety of using other parts of moringa during lactation; avoid using.
POSSIBLY SAFE ...when an extract of reishi mushroom is used orally and appropriately for up to one year (12,5485,70767,70774,70786,70799,70800,70801,70802). ...when whole powdered reishi mushroom is used orally and appropriately for up to 16 weeks (70776,70799,70800,70801,91433,91435,91436,91437,108309).
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using
POSSIBLY SAFE ...when used orally and appropriately, short-term. There is some clinical research showing that taking rhodiola extract up to 300 mg twice daily has been used without adverse effects for up to 12 weeks (13109,16410,17616,71172,96459,102283,103269).
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
Below is general information about the interactions of the known ingredients contained in the product Stress Relief. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Theoretically, taking ashwagandha with antidiabetes drugs might increase the risk of hypoglycemia.
Details
|
Theoretically, taking ashwagandha with antihypertensive drugs might increase the risk of hypotension.
Details
Animal research suggests that ashwagandha might lower systolic and diastolic blood pressure (19279). Theoretically, ashwagandha might have additive effects when used with antihypertensive drugs and increase the risk of hypotension.
|
Theoretically, taking ashwagandha might increase the sedative effects of benzodiazepines.
Details
There is preliminary evidence that ashwagandha might have an additive effect with diazepam (Valium) and clonazepam (Klonopin) (3710). This may also occur with other benzodiazepines.
|
Theoretically, taking ashwagandha might increase the sedative effects of CNS depressants.
Details
Ashwagandha seems to have sedative effects. Theoretically, this may potentiate the effects of barbiturates, other sedatives, and anxiolytics (3710).
|
Theoretically, taking ashwagandha might decrease the effects of immunosuppressants.
Details
|
Ashwagandha might increase the effects and adverse effects of thyroid hormone.
Details
Concomitant use of ashwagandha with thyroid hormones may cause additive therapeutic and adverse effects. Preliminary clinical research and animal studies suggest that ashwagandha boosts thyroid hormone synthesis and secretion (19281,19282,97292). In one clinical study, ashwagandha increased triiodothyronine (T3) and thyroxine (T4) levels by 41.5% and 19.6%, respectively, and reduced serum TSH levels by 17.4% from baseline in adults with subclinical hypothyroidism (97292).
|
Theoretically, taking Bacillus subtilis with antibiotic drugs might decrease the effectiveness of B. subtilis.
Details
Since B. subtilis preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms (1740). Tell patients to separate administration of antibiotics and B. subtilis preparations by at least 2 hours.
|
Theoretically, graviola might decrease concentrations of carbamazepine when used concomitantly.
Details
A study in rats shows that graviola extract reduces the area under the curve of carbamazepine by 46% and maximum concentration by 35% when compared with carbamazepine alone (112852).
|
Theoretically, moringa might have additive effects when used with antidiabetes drugs; however, research is conflicting.
Details
|
Theoretically, moringa might decrease the levels and clinical effects of CYP1A2 substrates.
Details
In vitro research shows that moringa extract induces CYP1A2 enzymes (111404).
|
Theoretically, moringa might increase or decrease levels of CYP3A4 substrates.
Details
Some in vitro research suggests that moringa inhibits cytochrome P450 3A4 (CYP3A4) (20576). However, other in vitro research suggests that moringa extract induces CYP3A4 enzymes (111404). A pharmacokinetic study in patients with HIV shows no change in the pharmacokinetics of nevirapine, which is partially metabolized by CYP3A4, when administered concomitantly with moringa leaf powder 1.85 grams daily for 14 days (97209).
|
Theoretically, moringa leaf can antagonize the effects of levothyroxine.
Details
Animal research suggests that moringa aqueous leaf extract might reduce serum triiodothyronine (T3) concentrations by inhibiting the peripheral conversion of thyroxine (T4) to T3 (16348).
|
Moringa leaf is unlikely to have a clinically significant interaction with nevirapine.
Details
Nevirapine is partially metabolized by cytochrome P450 3A4 (CYP3A4). In vitro evidence suggests that moringa inhibits CYP3A4 (20576). However, a pharmacokinetic study in patients with HIV shows no change in nevirapine pharmacokinetics when administered concomitantly with moringa leaf powder 1.85 grams daily for 14 days (97209).
|
Theoretically, moringa leaf extract might increase the levels and clinical effects of P-glycoprotein substrates.
Details
In vitro research shows that moringa leaf extract inhibits renal P-glycoprotein transport activity (107850). So far, this reaction has not been reported in humans.
|
Theoretically, high doses of reishi mushroom might increase the risk of bleeding.
Details
|
Theoretically, reishi mushroom might have additive effects with antidiabetes drugs.
Details
|
Theoretically, concurrent use of reishi mushroom with antihypertensive drugs might increase the risk of hypotension.
Details
|
Theoretically, taking rhodiola with antidiabetes drugs might increase the risk of hypoglycemia.
Details
|
Theoretically, taking rhodiola with antihypertensive drugs might increase the risk of hypotension.
Details
|
Theoretically, rhodiola might increase levels of drugs metabolized by CYP1A2.
Details
In vitro research shows that rhodiola inhibits CYP1A2. This effect is highly variable and appears to be dependent on the rhodiola product studied (96461). However, a clinical study in healthy young males found that taking rhodiola extract 290 mg daily for 14 days does not inhibit the metabolism of caffeine, a CYP1A2 substrate (96463).
|
Theoretically, rhodiola might increase levels of drugs metabolized by CYP2C9.
Details
In vitro research shows that rhodiola inhibits CYP2C9. This effect is highly variable and appears to be dependent on the rhodiola product studied (96461). Also, a clinical study in healthy young males found that taking rhodiola extract 290 mg daily for 14 days reduces the metabolism of losartan, a CYP2C9 substrate, by 21% after 4 hours (96463).
|
Theoretically, rhodiola might increase levels of drugs metabolized by CYP3A4.
Details
In vitro research shows that rhodiola inhibits CYP3A4 (19497,96461). This effect is highly variable and appears to be dependent on the rhodiola product studied (96461). However, a clinical study in healthy young males found that taking rhodiola extract 290 mg daily for 14 days does not inhibit the metabolism of midazolam, a CYP3A4 substrate (96463).
|
Theoretically, rhodiola use might interfere with immunosuppressive therapy.
Details
|
Rhodiola might increase the levels and adverse effects of losartan.
Details
A clinical study in healthy young males found that taking rhodiola extract 290 mg daily for 14 days reduces the metabolism of losartan, a CYP2C9 substrate, by 21% after 4 hours (96463).
|
Theoretically, rhodiola might increase levels of P-glycoprotein substrates.
Details
In vitro research shows that rhodiola inhibits P-glycoprotein (19497). Theoretically, using rhodiola with P-glycoprotein substrates might increase drug levels and potentially increase the risk of adverse effects.
|
Below is general information about the adverse effects of the known ingredients contained in the product Stress Relief. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General
...Orally, ashwagandha seems to be well-tolerated.
Topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.
Most Common Adverse Effects:
Orally: Diarrhea, gastrointestinal upset, nausea, and vomiting. However, these adverse effects do not commonly occur with typical doses.
Serious Adverse Effects (Rare):
Orally: Some case reports raise concerns about acute liver failure, hepatic encephalopathy, and the need for liver transplantation with ashwagandha treatment.
Dermatologic ...Orally, dermatitis has been reported in three of 42 patients in a clinical trial (19276).
Endocrine ...A case report describes a 73-year-old female who had taken an ashwagandha root extract (unspecified dose) for 2 years to treat hypothyroidism which had been previously managed with levothyroxine. The patient was diagnosed with hyperthyroidism after presenting with supraventricular tachycardia, chest pain, tremor, dizziness, fatigue, irritability, hair thinning, and low thyroid stimulating hormone (TSH) levels. Hyperthyroidism resolved after discontinuing ashwagandha (108745).
Gastrointestinal ...Orally, large doses may cause gastrointestinal upset, diarrhea, and vomiting secondary to irritation of the mucous and serous membranes (3710). When taken orally, nausea and abdominal pain (19276,110490) and gastritis and flatulence (90651) have been reported.
Genitourinary ...In one case report, a 28-year-old male with a decrease in libido who was taking ashwagandha 5 grams daily over 10 days subsequently experienced burning, itching, and skin and mucous membrane discoloration of the penis, as well as an oval, dusky, eroded plaque (3 cm) with erythema on the glans penis and prepuce (32537).
Hepatic ...Orally, ashwagandha in doses of 154-1350 mg daily has played a role in several case reports of liver injury. In most of these cases, other causes of liver injury were excluded, and liver failure did not occur. Symptoms included jaundice, pruritus, malaise, fatigue, lethargy, weight loss, nausea, diarrhea, abdominal pain, stool discoloration, and dark urine. Symptom onset was typically 5-180 days from first intake, although in some cases onset occurred after more than 12 months of use (102686,107372,110490,110491,111533,111535,112111). Laboratory findings include elevated aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, and serum bilirubin (112111). In most cases, liver enzymes normalized within 1-5 months after discontinuation of ashwagandha (102686,107372,110491,111535,112111). However, treatment with corticosteroids, lactulose, ornithine, ursodeoxycholic acid, and plasmapheresis, among other interventions, was required in one case (111533). Rarely, use of oral ashwagandha has been reported to cause hepatic encephalopathy and liver failure requiring liver transplantation (110490).
Neurologic/CNS ...Orally, ashwagandha has been reported to cause drowsiness (110492). Headache, neck pain, and blurry vision have been reported in a 47-year-old female taking ashwagandha, cannabis, and venlafaxine. Imaging over the course of multiple years and hospital admissions indicated numerous instances of intracranial hemorrhage and multifocal stenosis of intracranial arteries, likely secondary to reversible cerebral vasoconstriction syndrome (RCVS) (112113). It is unclear whether the RCVS and subsequent intracranial hemorrhages were precipitated by ashwagandha, cannabis, or venlafaxine.
General
...Orally, Bacillus subtilis seems to be well tolerated by most patients.
Serious Adverse Effects (Rare):
Orally: There is concern that B. subtilis may cause bacteremia in certain patients.
Dermatologic ...Orally, itching and redness were reported rarely (110848).
Gastrointestinal ...Orally, diarrhea has been reported rarely (110846).
Immunologic
...There are cases of Bacillus subtilis var.
natto bacteremia and meningitis in patients with frequent consumption of natto, soybeans fermented with B. subtilis var. natto (110844,110862). A 70-year-old female recovered from bacteremia after this consumption was stopped and she was treated with vancomycin. It was hypothesized that this infection was due to an immunocompromised state related to age, type 2 diabetes, kidney failure, multiple myeloma, coronavirus disease 2019 (COVID-19), and treatment with immunosuppressive therapy (110844). In a 67-year-old female, bacterial entry was suspected to be related to erosion of her esophagus (110862).
There have been other rare cases of bacteremia or infections due to B. subtilis. These cases are unlikely to be related to intake or supplementation but to an immunocompromised state and/or introduction of bacteria to the body via non-oral routes. Cases of bacteremia include a newborn infant with sepsis, an adult with esophageal perforation, and a patient undergoing bone marrow transplantation subjected to contaminated materials (110834,110837,110840). There is also a case of cholangitis in a 15-year-old child with a recent kidney transplant related to polycystic kidney disease (110838).
Neurologic/CNS ...Orally, one case of headache was reported in a clinical trial (110847).
Pulmonary/Respiratory ...Orally, two cases of nasal obstruction were reported in a clinical trial (110847).
Other ...Orally, an acute episode of mild pain was reported in a clinical trial (110847).
General
...Orally, regular consumption of graviola may be unsafe.
Most Common Adverse Effects:
Orally: Epigastrium pain, nausea.
Serious Adverse Effects (Rare):
Orally: Movement disorders, myeloneuropathy.
Gastrointestinal ...In one clinical study, some patients reported nausea and burning pain in the epigastrium after taking graviola leaf extract 300 mg daily (95045).
Neurologic/CNS ...Orally, regular consumption of graviola fruit may cause movement disorders and myeloneuropathy. The symptoms of these disorders are similar to Parkinson disease (7854). In addition, a large observational study in patients with Parkinson disease suggests that even low cumulative consumption of graviola fruit, juice, or any amount of herbal tea containing graviola is associated with worsened motor and cognitive symptoms (112854).
General
...Orally and topically, moringa leaf and seed seem to be well tolerated.
Orally, moringa root and root bark might be unsafe. However, a thorough evaluation of safety outcomes has not been conducted.
Most Common Adverse Effects:
Orally: Transient diarrhea.
Serious Adverse Effects (Rare):
Orally: Allergic reactions, including anaphylaxis, have been reported.
Cardiovascular ...Orally, a case of bilateral pulmonary embolism after a 5-month history of taking moringa leaf extract is reported in a 63-year-old female without other risks for venous thromboembolism. The patient recovered with standard anticoagulant treatment. Researchers speculate that possible procoagulant effects of moringa may have played a role in this event (110644).
Dermatologic ...Orally, Stevens-Johnson syndrome has been linked to the consumption of moringa leaves. A 53-year-old male presented with fever and generalized maculopapular rash 14 hours after eating food containing moringa leaves. Painful oral ulcers developed by the next day. The patient also reported a similar episode of oral ulcers after eating food containing moringa leaves three months earlier. The patient was treated with oral prednisolone and omeprazole and recovered within two weeks. Researchers speculate that the immunomodulatory effects of moringa may have played a role in this reaction (99876). There are also cases of fixed food eruption to moringa. In one case, suspected fixed food eruption occurred on the trunk and face of a 60-year-old female, reoccurring 8 hours after self reintroduction (112641).
Gastrointestinal ...Orally, moringa leaf powder can cause diarrhea. In a clinical trial, taking moringa leaf powder 8 grams daily resulted in transient diarrhea in 4 of 16 patients (25%) (105470).
Immunologic ...Orally, cases of anaphylaxis are reported after ingestion of young moringa leaves and seedpods. In these cases, positive skin-prick testing confirmed moringa as the causative allergen. The patients recovered after standard treatment (110597,110643). There are also cases of fixed food eruption to moringa. In one case, suspected fixed food eruption occurred on the trunk and face of a 60-year-old female, reoccurring 8 hours after self reintroduction (112641).
General
...Orally, reishi mushroom is generally well tolerated.
Most Common Adverse Effects:
Orally: Dizziness, dry mouth, itching, nausea, rash, and stomach upset.
Dermatologic ...Orally, reishi mushroom can cause itching, rash, and other skin reactions (12,5479).
Gastrointestinal ...Orally, reishi mushroom can cause dryness of the mouth, throat, or nasal cavity, nausea, stomach upset, and, more rarely, diarrhea (12,70779,91438,108309).
Hematologic ...Orally, reishi mushroom can cause nosebleed and bloody stools (12,91438).
Hepatic ...One case of hepatotoxicity and one case of fatal fulminant hepatitis have been reported in patients who had used reishi mushroom powder for 1-2 months (70766). There is a case report of a 61-year-old male with hypereosinophilia associated with hepatic nodules following the use of reishi mushroom powder for about 2 months. Symptoms resolved after discontinuation of the product. Although these side effects were thought to be associated with the use of reishi mushroom powder, it is unclear if other factors played a role. The patient had been taking tegafur, gimeracil, and oteracil potassium for about 4 months following anterior resection for rectal adenocarcinoma but discontinued these agents and initiated reishi mushroom due to liver injury (108312).
Neurologic/CNS ...Orally, reishi mushroom can cause dizziness (91438). Other rare symptoms include insomnia and headache (70776,70779).
Pulmonary/Respiratory ...Respiratory allergy to reishi spores can occur (12,5479). Sore throat and runny nose have also been reported (70776,91438).
General
...Orally, rhodiola seems to be well tolerated.
Most Common Adverse Effects:
Orally: Dizziness, increased or decreased production of saliva.
Gastrointestinal ...Orally, rhodiola extract may cause dry mouth or excessive saliva production (16410,16411).
Neurologic/CNS ...Orally, rhodiola extract can cause dizziness (16410).